| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$14 |
Media Release - 2025 Full Year Results
|
29 Aug 2025 8:55AM |
$0.074 |
$0.056 |
fallen by
24.32%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- K2 Asset Management Holdings Ltd reported 2025 financial year results.
- Total revenue increased by 17% to AUD $6,152,771.
- Net profit after tax was AUD $344,687.
- Assets Under Management (AUM) reached AUD $5 billion, a 14% increase.
- A fully franked dividend of 0.5 cent per share was declared.
- Company focuses on consistent and sustainable earnings.
- Strategic repositioning supported by three core service pillars.
- Investment advisory services expanded, led by the new CIO Office.
- Strong cash position with AUD $8.6 million on balance sheet.
- Future growth plans include exploring mergers and acquisitions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$14 |
Media Release - 2025 Full Year Results
|
29 Aug 2025 8:55AM |
$0.074 |
$0.056 |
fallen by
24.32%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- 17% increase in revenue to AUD $6,152,771.
- Net profit after tax of AUD $344,687.
- AUM grew to AUD $5 billion, a 14% increase.
- Declared a fully franked dividend of 0.5 cents per share.
- Focus on sustainable revenue from core business pillars.
- Expansion of investment advisory services with the CIO Office.
- Exploration of mergers and acquisitions for growth.
- Strong cash reserves of AUD $8.6 million.
- Positive revenue growth outlook supported by client relationships and fiduciary needs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$14 |
Appendix 4G - Key to Corporate Governance Disclosures
|
29 Aug 2025 8:54AM |
$0.074 |
$0.056 |
fallen by
24.32%
|
|
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$14 |
Appendix 4E and Annual Report - 30 June 2025
|
29 Aug 2025 8:54AM |
$0.074 |
$0.056 |
fallen by
24.32%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax of $344,687 for the year ended 30 June 2025.
- Revenue increased by 17.10% to $6,152,771.
- No dividends were declared for the year.
- Total equity stands at $8,436,146.
- Basic earnings per share improved to 0.14 cents.
- Total remuneration for key management personnel was $1,328,798.
- No performance-based bonuses were paid to key management personnel.
- Liquidity risk managed through cash reserves and short-term investments.
- Credit risk is low due to control over investment funds.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VRX Silica Limited (VRX) ORDINARY FULLY PAID |
Materials |
$30 |
Trading Halt
|
29 Aug 2025 8:53AM |
$0.115 |
$0.035 |
fallen by
69.57%
|
|
VRX - Price-sensitive ASX Announcement
Full Release
Key Points
- VRX Silica Limited requests a trading halt.
- The halt is due to an impending material announcement.
- The announcement is regarding environmental approval for the Arrowsmith North Silica Sand Project.
- The halt will last until the announcement or 2 September 2025.
- No additional information or reasons against the halt were provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VRX Silica Limited (VRX) ORDINARY FULLY PAID |
Materials |
$30 |
Trading Halt
|
29 Aug 2025 8:53AM |
$0.115 |
$0.035 |
fallen by
69.57%
|
|
VRX - Price-sensitive ASX Announcement
Full Release
Key Points
- VRX Silica Limited requested a trading halt for its ordinary shares.
- The trading halt is pending a material announcement regarding the Arrowsmith North Silica Sand Project.
- The halt is requested to remain until the announcement is made or until normal trading resumes on 1 September 2025.
- VRX Silica is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Dairy Nutritionals Group (AHF) ORDINARY FULLY PAID |
Consumer Staple |
$17 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 8:53AM |
$0.042 |
$0.021 |
fallen by
50%
|
|
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
Variation of CEO Employment Agreement & LTIP grants
|
29 Aug 2025 8:53AM |
$0.120 |
$0.130 |
risen by
8.33%
|
|
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Next Science reports 1H FY25 Result
|
29 Aug 2025 8:53AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Product sales declined to US$10.5 million, down 7% from the previous year.
- Direct sales of XPERIENCE increased by 54%.
- Gross profit was US$8.7 million with a gross margin of 83%.
- Operating expenses reduced by 17%.
- Adjusted EBITDA loss improved to US$2.8 million.
- Closing cash balance was US$1.0 million with US$4.5 million debt.
- Shareholders approved the sale of most assets to OSARTIS GmbH.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Next Science reports 1H FY25 Result
|
29 Aug 2025 8:53AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Product sales of US$10.5 million, down 7% on pcp.
- XPERIENCE product sales increased by 54%.
- Gross profit of US$8.7 million, gross margin increased to 83%.
- Operating expenses reduced by 17%.
- Adjusted EBITDA loss improved by 42% to US$2.8 million.
- Net operating cash outflows reduced to US$2.8 million.
- Closing cash balance of US$1.0 million.
- Majority asset sale to OSARTIS GmbH approved.
- Periprosthetic Joint Infection study underway with 2,191 patients enrolled.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Dairy Nutritionals Group (AHF) ORDINARY FULLY PAID |
Consumer Staple |
$17 |
Appendix 4E and Annual Report to Shareholders
|
29 Aug 2025 8:52AM |
$0.042 |
$0.021 |
fallen by
50%
|
|
AHF - Price-sensitive ASX Announcement
Full Release
Key Points
- 14% increase in revenue from ordinary activities to $7.168 million.
- 29% reduction in loss after tax to $5.261 million.
- No dividends declared for the financial year.
- Total assets decreased from $30.35 million in 2024 to $25.09 million in 2025.
- Liabilities reduced significantly from $3.62 million to $1.44 million.
- Comprehensive audited financial statements included.
- Details on directors, remuneration, and shareholding structure provided.
- Emphasis on strategic financial management including share-based payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Dairy Nutritionals Group (AHF) ORDINARY FULLY PAID |
Consumer Staple |
$17 |
Appendix 4E and Annual Report to Shareholders
|
29 Aug 2025 8:52AM |
$0.042 |
$0.021 |
fallen by
50%
|
|
AHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Total FY25 revenue was $7.17 million, a 14% increase over FY24.
- The infant formula business grew nearly fourfold.
- EBIT loss was reduced by 29% to $5.26 million.
- Net assets decreased to $23.65 million due to operating losses.
- The group is debt-free at the end of FY25.
- Strategic focus on expanding the infant formula market in China.
- Cost control measures reduced corporate costs by 13%.
- The group has significant growth potential in the infant formula market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Half Year Report & Appendix 4D
|
29 Aug 2025 8:52AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue declined to USD 10.49 million from USD 11.24 million year-on-year.
- Operating in North America and Australia/New Zealand as a single segment.
- Net loss of USD 4.69 million compared to USD 5.84 million previously.
- High expenses in selling, distribution, and R&D impacted financials.
- Secured a USD 4.5 million loan facility with TIGA Trading Pty Ltd.
- Recorded a comprehensive loss, including foreign currency impacts.
- Total assets at USD 9.46 million, liabilities at USD 10.02 million.
- Anticipated asset sale completion to OSARTIS in September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Half Year Report & Appendix 4D
|
29 Aug 2025 8:52AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Next Science Limited reported a revenue of $10.49 million for the half-year ended 30 June 2025, a decrease from $11.24 million in the prior year.
- The company operates in a single segment across two geographical areas: North America and Australia/New Zealand.
- For the half-year, North America contributed $7.61 million in revenue and Australia/New Zealand contributed $2.87 million.
- Total comprehensive loss for the period was $4.82 million, compared to a loss of $6.03 million in the previous year.
- Cash and cash equivalents at the end of the period were $971,237, down from $1.67 million at the start of the period.
- Current liabilities increased to $4.84 million from $3.22 million, while non-current liabilities rose to $5.18 million from $2.55 million.
- The company remains focused on its core technology used in combating infections, with ongoing investments in research and development.
- Earnings per share were reported as -1.60 cents compared to -2.00 cents in the previous year.
- The company is managing a high level of accumulated losses amounting to $93.79 million as of 30 June 2025.
- Net assets have decreased significantly, reflecting a total deficiency in equity of $557,034 at the end of the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enero Group Limited (EGG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Initial Director's Interest Notice
|
29 Aug 2025 8:52AM |
$0.955 |
$0.300 |
fallen by
68.59%
|
|
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
Corporate Governance Statement & Appendix 4G
|
29 Aug 2025 8:52AM |
$0.120 |
$0.130 |
risen by
8.33%
|
|
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
- |
Appendix 4E and 2025 Annual Report
|
29 Aug 2025 8:52AM |
$0.032 |
$0.034 |
risen by
6.25%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Income from ordinary activities increased by 41.8% to AUD 1,587,462.
- Net loss reduced by 13.2% to AUD 5,332,421.
- No dividends were declared during the current financial period.
- Positive results in Phase 2a clinical trials for fibromyalgia and IBS using TRP-8802.
- R&D loan facility secured for AUD 2,600,000 for future activities.
- Total comprehensive income showed a reduction in losses compared to the prior year.
- Ongoing development of TRP-8803 with exclusive biomarker development agreement.
- The company continues to invest heavily in research and development.
- No significant environmental regulations impacted the company.
- An independence declaration was provided by BDO Audit Pty Ltd, the company's auditor.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:51AM |
$0.120 |
$0.130 |
risen by
8.33%
|
|
AFL - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue growth of 27% compared to FY24.
- Normalised NPBT of $1.4 million attributable to AF Legal Group Ltd owners, up 77%.
- Acquisition of Armstrong Criminal & Family Law practices.
- Cultural transition to a people-first and practice-led approach.
- Introduction of Project Titan, a cloud-based PMS and DMS platform.
- Strong revenue growth in Family Law segment.
- Increase of 20% in lawyers and 30% in fee earners.
- Average weekly revenue exceeded $600k in Q4 FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:51AM |
$0.120 |
$0.130 |
risen by
8.33%
|
|
AFL - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 Revenue growth of 27%
- Normalised NPBT attributable to AF Legal Group owners was $1.4 million
- Acquisition of Armstrong Legal Criminal & Family Law practices
- Cultural shift towards a people-first focus
- Investment in Project Titan platform
- Net cash outflow for FY25 of $0.1 million
- Strong revenue momentum and profitability improvements
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$36,950 |
Update - Notification of buy-back - ALL
|
29 Aug 2025 8:51AM |
$72.880 |
$61.400 |
fallen by
15.75%
|
|
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$529 |
FY2025 Financial Results
|
29 Aug 2025 8:51AM |
$1.815 |
$1.275 |
fallen by
29.75%
|
|
BOE - Price-sensitive ASX Announcement
Full Release
Key Points
- Boss Energy reported a net loss after tax of $34.2 million for FY2025.
- Total revenue for FY2025 was $75.6 million from the sale of 650Klbs of purchased uranium.
- Positive operating net cash flow of $17.4 million.
- Cash and liquid assets of $224.3 million with no debt were recorded.
- Uranium inventory amounted to 1,409Klbs, with strategic accumulation during the year.
- Average realized uranium sale price was US$78.4/lb.
- The company remains strategically under-contracted for future uranium price exposure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$529 |
FY2025 Financial Results
|
29 Aug 2025 8:51AM |
$1.815 |
$1.275 |
fallen by
29.75%
|
|
BOE - Price-sensitive ASX Announcement
Full Release
Key Points
- First full financial year of production at Honeymoon and Alta Mesa.
- Net loss after tax of $34.2 million driven by non-cash impacts.
- Total revenue of $75.6 million primarily from purchased uranium sales.
- Positive operating cash flow of $17.4 million.
- Strong cash position with $224.3 million in cash and liquid assets.
- Zero debt maintained by the company.
- Inventory accumulation of 1,409,000 pounds of uranium.
- Average realized uranium sale price was US$78.4 per pound.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enero Group Limited (EGG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Director Appointment - Ian Ball
|
29 Aug 2025 8:51AM |
$0.955 |
$0.300 |
fallen by
68.59%
|
|
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$30 |
Appendix 4G & Corporate Governance Statement
|
29 Aug 2025 8:51AM |
$0.235 |
$0.170 |
fallen by
27.66%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$155 |
2025 Half Year Report and Appendix 4D
|
29 Aug 2025 8:51AM |
$0.290 |
$0.355 |
risen by
22.41%
|
|
FDV - Price-sensitive ASX Announcement
Full Release
Key Points
- Group statutory revenue decreased by 5% to A$33.3 million.
- Operating expenses decreased by 10%, leading to a 71% increase in statutory EBITDA.
- Net loss after tax was A$1.7 million, a 16% increase from the previous year.
- Strong performance in the LATAM region, with Fincaraiz and Encuentra24 showing revenue and EBITDA growth.
- No dividends were declared or paid for the reporting period.
- Foreign exchange losses and other financial pressures contributed to the net loss.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
